22157.jpg
Global Antimicrobial Resistance Diagnostic Market Report 2022-2027: Key Large Pathogen Opportunities in this Space and Developed Market Forecasts
January 24, 2022 04:38 ET | Research and Markets
Dublin, Jan. 24, 2022 (GLOBE NEWSWIRE) -- The "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, with Executive Guides and Customization" report has been...
22157.jpg
Global Antibiotics Markets Report 2021: Market was Valued at $46.66 Billion in 2020 - Forecast to 2026
January 04, 2022 07:08 ET | Research and Markets
Dublin, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The "Global Antibiotics Market - Analysis By Drug Class (Beta-Lactams, Cephalosporins, Lipopeptide, Others), Mechanism, By Region, By Country (2021...
Summit-logo-RGB.png
Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021
September 30, 2021 09:00 ET | Summit Therapeutics Inc.
Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an important ePoster at IDWeek 2021. IDWeek is...
22157.jpg
Global Anti-Infective Drugs Market to Recover by 2025 to Reach $158.29 Billion
September 23, 2021 05:53 ET | Research and Markets
Dublin, Sept. 23, 2021 (GLOBE NEWSWIRE) -- The "Anti-Infective Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering....
22157.jpg
Global Antibiotic Resistance Markets Report 2021: Therapeutic Technology Development Opportunities by Pathogen and Therapy Type 2020-2024
August 31, 2021 05:53 ET | Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type 2020 to 2024" report has been added to ResearchAndMarkets.com's offering. ...
Summit logo.png
Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole
July 12, 2021 08:29 ET | Summit Therapeutics Inc.
Cambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st European...
HelixBind_Logo_AS2-no BG (2018).png
HelixBind Awarded $3MM NIH Grant to Support Testing of Its RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis
June 17, 2021 08:30 ET | HelixBind
BOXBOROUGH, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
22157.jpg
Global Antibiotic Resistance Markets Report 2021 with Profiles of 100+ Biotechnology Companies
January 25, 2021 05:08 ET | Research and Markets
Dublin, Jan. 25, 2021 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type 2020 to 2024" report has been added to ResearchAndMarkets.com's offering. ...
22157.jpg
Antibiotics Technologies and Markets, 2025
January 12, 2021 04:38 ET | Research and Markets
Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Antibiotics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for antibiotics should...
22157.jpg
Global Antibiotic Resistance Markets to 2024: Examine 6 Key Opportunity Areas
October 01, 2020 04:09 ET | Research and Markets
Dublin, Oct. 01, 2020 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics By Pathogen and Therapy Type 2020 To 2024" report has been added to ResearchAndMarkets.com's offering. ...